-
-
-
-
-
-
-
Xenetic Biosciences (XBIO) Enters Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
-
-
-
-
-
-
-
Xenetic Biosciences (XBIO) Reports Positive Data from PJSC Pharmsynthez's Pivotal Phase 3 Clinical Trial Utilizing PolyXen
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART(TM) Platform
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. to Present at BIO Investor Forum
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

